<DOC>
	<DOCNO>NCT01461538</DOCNO>
	<brief_summary>This open-label , multicenter , phase 2 clinical trial evaluate antitumor activity brentuximab vedotin single agent patient CD30-positive nonlymphomatous malignancy .</brief_summary>
	<brief_title>Brentuximab Vedotin Patients With CD30-positive Nonlymphomatous Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologicallyconfirmed central review CD30positive nonlymphomatous malignancy Have fail , refuse , deem ineligible standard therapy Measurable disease Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 Karnofsky Lansky Performance Status score great equal 70 Primary diagnosis lymphoma central nervous system ( CNS ) malignancy History another primary invasive malignancy definitively treated remission least 3 year Evidence active cerebral/meningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Acute Lymphoid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Anemia , Refractory , Excess Blasts</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Monomethyl Auristatin E</keyword>
</DOC>